放射線治療の世界市場予測(~2023年)

◆英語タイトル:Radiotherapy Market by Type (External (IGRT, IMRT, 3D-CRT, Stereotactic), Brachytherapy (LDR, HDR)), Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Application (Prostate, Breast), End User (Hospital) - Forecasts to 2023
◆商品コード:MD 1773
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2019年1月10日
◆ページ数:227
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

放射線治療の世界市場は、2018年の56億米ドルから2023年には68億米ドルに達し、この期間中4.1%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、世界的ながん罹患率の増加、臨床試験における放射線療法の採用の増加、世界中での放射線療法センターの数の増加などが考えられます。一方で、新興国の未発達な公衆衛生インフラ、訓練を受けた熟練放射線腫瘍医の不足、そして放射線療法治療選択肢に限りがあることと治療費が高価なことにより、市場の成長が妨げられる可能性があります。当調査レポートでは、放射線治療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、種類別(外部照射療法、近接照射療法)分析、製品別(LINAC、サイバーナイフ、ガンマナイフ、トモセラピー、粒子線治療、サイクロトロン)分析、用途別(前立腺がん、乳がん)分析、エンドユーザー別(病院)分析、放射線治療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

“The radiotherapy market is projected to grow at a CAGR of 4.1% during the forecast period”The global radiotherapy market is projected to reach USD 6.8 billion by 2023 from USD 5.6 billion in 2018, at a CAGR of 4.1%. Growth in this market is largely driven by factors such as the growing global prevalence of cancer, increasing adoption of radiotherapy in clinical trials, and the increasing number of radiotherapy centers worldwide. However, the underdeveloped public health infrastructure in emerging countries, shortage of trained and skilled radiation oncologists, and the limited access to and affordability of various radiotherapy treatment options are the major factors that are expected to restrain the growth of this market during the forecast period.

“The linear accelerators segment is expected to account for the largest market share during the forecast period”
Based on product type, the external beam radiotherapy products market is segmented into linear accelerators (LINAC), particle therapy systems, and conventional cobalt-60 teletherapy units. The linear accelerators segment is expected to account for the largest share of this market in 2018, driven by the development of advanced systems and their growing adoption across the globe.

“The seeds segment is expected to hold the largest share of the internal beam radiotherapy/brachytherapy products market during the forecast period”
Based on product type, the internal beam radiotherapy/brachytherapy products market is segmented into seeds, applicators, afterloaders, and electronic brachytherapy products. The seeds segment is expected to account for the largest share of this market in 2018. The large share of this segment can be attributed to the growing availability of seeds; advances in patient selection, treatment planning, technique, and technology; and growing applications in prostate cancer treatment.

“Europe to account for the second-largest share of the global market in 2018”
The radiotherapy market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is expected to account for the second-largest share of the global radiotherapy market in 2018. The growing incidence of cancer, supportive government initiatives, and the implementation of radiotherapy training programs & conferences/symposiums are the major factors propelling the demand for radiotherapy products in Europe. Furthermore, several key market players are focusing on enhancing their radiotherapy products to improve the quality of patient care across Europe.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (25%), Tier 2 (30%), and Tier 3 (45%)
• By Designation: C-level (26%), Director-level (30%), and Others (44%)
• By Region: North America (35%), Europe (26%), APAC (23%), and RoW (16%)

The major players in the market include Varian Medical Systems, Inc. (US), Elekta AB (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd. (India), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc (US), P-cure Ltd. (Israel), Theragenics Corporation (US), and C.R.Bard, Inc. (US), among others.

Research Coverage
This report studies the radiotherapy market based on type, product type, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the radiotherapy market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 23
1.5 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 26
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 27
2.1.2.1 Key data from primary sources 28
2.2 MARKET SIZE ESTIMATION 30
2.2.1 PRODUCT-BASED MARKET ESTIMATION 30
2.2.2 PRIMARY RESEARCH VALIDATION 32
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS 34
2.4.1 LIMITATIONS 34
2.4.2 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 40
4.1 RADIOTHERAPY MARKET OVERVIEW 40
4.2 EUROPE: EXTERNAL RADIOTHERAPY MARKET, BY TYPE, 2018 41
4.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE 42
4.4 EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION 43
4.5 REGIONAL ANALYSIS: RADIOTHERAPY MARKET, BY END USER 44
4.6 RADIOTHERAPY MARKET, BY COUNTRY 45

5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
5.2.1 DRIVERS 47
5.2.1.1 Technological advancements 47
5.2.1.2 Rising prevalence of cancer 48
5.2.1.3 Increasing number of conferences and symposia focusing on spreading awareness about the benefits of radiotherapy 50
5.2.1.4 Growing use of particle therapy for cancer treatment 50
5.2.2 RESTRAINTS 51
5.2.2.1 Lack of adequate healthcare infrastructure 51
5.2.2.2 Shortage of trained personnel 51
5.2.2.3 Affordability and accessibility of treatment 52
5.2.2.4 Complex nature of radiotherapy 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emerging markets 53
5.2.3.2 Growing government and private investments to meet the increasing demand for cancer treatment 54
5.2.3.3 Improving reimbursement scenario 54
5.2.4 CHALLENGES 55
5.2.4.1 Difficulties in visualizing tumors during radiotherapy procedures 55
5.2.4.2 Risk of radiation exposure 55
5.3 INDUSTRY TRENDS 56
5.3.1 GROWING ADOPTION OF PENCIL-BEAM SCANNING 56
5.3.2 GROWING NUMBER OF COLLABORATIONS AND ACQUISITIONS 56
6 RADIOTHERAPY MARKET, BY PRODUCT TYPE 58
6.1 INTRODUCTION 59
6.2 EXTERNAL BEAM RADIOTHERAPY 60
6.2.1 LINEAR ACCELERATORS 61
6.2.1.1 Conventional Linear Accelerators 62
6.2.1.1.1 Lower equipment and maintenance cost will drive the market for conventional LINACs 62
6.2.1.2 Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators 63
6.2.1.2.1 Automation and real-time tracking features have ensured demand for stereotactic advanced LINAC 63
6.2.1.2.2 Gamma Knife 64
6.2.1.2.2.1 The Gamma Knife system is considered a gold standard for brain tumor treatment 64
6.2.1.2.3 CyberKnife 65
6.2.1.2.3.1 CyberKnife offers a precise radiation delivery method with specialized tracking and robotic correction capabilities 65

6.2.1.2.4 TomoTherapy 66
6.2.1.2.4.1 360-degree (helical) radiation treatment with TomoTherapy is adding growth opportunities to this segment 66
6.2.2 PARTICLE THERAPY SYSTEMS 67
6.2.2.1 Cyclotrons 68
6.2.2.1.1 Leading players in the particle therapy market mainly manufacture cyclotrons 68
6.2.2.2 Synchrotrons 69
6.2.2.2.1 Increasing investment for the development of synchrotron facilities are contributing to market growth 69
6.2.2.3 Synchrocyclotrons 70
6.2.2.3.1 High space requirements of synchrocyclotrons are limiting its widespread adoption 70
6.2.3 CONVENTIONAL COBALT-60 TELETHERAPY UNITS 71
6.2.3.1 High cost and risk of radiation exposure with cobalt-60 radioisotopes have hindered the growth of this segment 71
6.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 72
6.3.1 SEEDS 74
6.3.1.1 Adverse side-effects associated with seeds limit their adoption 74
6.3.2 APPLICATORS 75
6.3.2.1 Manual applicators pose a high risk of radiation exposure to the patients and staff 75
6.3.3 AFTERLOADERS 76
6.3.3.1 Modern afterloaders offer proper positioning and better control of isotopes inside the patient body 76
6.3.4 ELECTRONIC BRACHYTHERAPY PRODUCTS 77
6.3.4.1 Electronic brachytherapy requires low amount of shielding than alternatives 77
6.4 SYSTEMIC RADIOTHERAPY 78
6.4.1 IOBENGUANE (I-131) 78
6.4.1.1 Increasing incidence of thyroid cancer is driving the growth of this segment 78
6.4.2 SAMARIUM-153 78
6.4.2.1 Samarium-153 has wide applications for bone metastasis 78
6.4.3 RHENIUM-186 79
6.4.3.1 Lack of insurance coverage with the use of Rhenium-186 restricting its growth 79
6.4.4 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS 79

7 RADIOTHERAPY MARKET, BY TYPE 80
7.1 INTRODUCTION 81
7.2 EXTERNAL BEAM RADIOTHERAPY 81
7.2.1 IMAGE-GUIDED RADIOTHERAPY 83
7.2.1.1 Image-guided radiotherapy is widely used to the treatment of deep-seated tumors 83
7.2.2 3D CONFORMAL RADIOTHERAPY 84
7.2.2.1 Multiple beams with 3D-CRT allow precise radiation conforming to the tumor size and shape 84
7.2.3 INTENSITY-MODULATED RADIOTHERAPY 85
7.2.3.1 Volumetric Arc Therapy 86
7.2.3.1.1 Advancements in the VMAT technology driving its widespread adoption 86
7.2.3.2 TomoTherapy 87
7.2.3.2.1 Minimal exposure to normal tissues – A major advantage of TomoTherapy 87
7.2.4 STEREOTACTIC THERAPY 88
7.2.4.1 Stereotactic therapy offers a minimally invasive alternative to ablation surgeries 88
7.2.5 PARTICLE THERAPY 89
7.2.5.1 Particle therapy is increasingly being adopted as a primary mode of treatment for various cancer types 89
7.3 INTERNAL BEAM RADIOTHERAPY 91
7.3.1 LOW-DOSE-RATE BRACHYTHERAPY 93
7.3.1.1 Lower risk of radiation exposure to the surrounding tissues with LDR supporting market growth 93
7.3.2 HIGH-DOSE-RATE BRACHYTHERAPY 94
7.3.2.1 Better patient care with HDR is driving its widespread adoption 94
7.3.3 PULSED-DOSE-RATE BRACHYTHERAPY 94
7.3.3.1 Pulsed-dose rate brachytherapy combines the advantages of HDR and LDR brachytherapy 94
7.4 SYSTEMIC RADIOTHERAPY 95
7.4.1 INTRAVENOUS RADIOTHERAPY 95
7.4.1.1 Intravenous route of brachytherapy results in maximum bioavailability 95
7.4.2 ORAL RADIOTHERAPY 96
7.4.2.1 Longer distribution time associated with the oral mode of radiation delivery limiting its demand 96
7.4.3 INSTILLATION RADIOTHERAPY 96
7.4.3.1 Lesser localization with instillation brachytherapy is limiting its widespread adoption 96

8 RADIOTHERAPY MARKET, BY APPLICATION 97
8.1 INTRODUCTION 98
8.2 EXTERNAL BEAM RADIATION THERAPY 98
8.2.1 PROSTATE CANCER 100
8.2.1.1 High incidence of prostate cancer will drive the demand for EBRT 100
8.2.2 BREAST CANCER 101
8.2.2.1 Adoption of advanced EBRT systems and increasing research will drive market growth 101
8.2.3 LUNG CANCER 102
8.2.3.1 Radiotherapy can be used as solo or combination therapy for lung cancer 102
8.2.4 HEAD AND NECK CANCER 103
8.2.4.1 Benefits of external radiotherapy will support its use in head and neck cancer treatment 103
8.2.5 COLORECTAL CANCER 104
8.2.5.1 Availability of alternative therapeutic options limits the growth of this segment 104
8.2.6 OTHER CANCERS 105
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 106
8.3.1 PROSTATE CANCER 107
8.3.1.1 Rapidity and precision of brachytherapy in prostate cancer treatment have driven market growth 107
8.3.2 GYNECOLOGICAL CANCER 108
8.3.2.1 Availability of alternatives hinders the adoption of brachytherapy in gynecological cancer treatment 108
8.3.3 BREAST CANCER 109
8.3.3.1 Precision and rapid treatment times are driving the use of brachytherapy in breast cancer applications 109
8.3.4 CERVICAL CANCER 110
8.3.4.1 A combination of brachytherapy and chemotherapy is typically used for cervical cancer treatment 110
8.3.5 PENILE CANCER 111
8.3.5.1 Advantages of brachytherapy in penile cancer treatment have driven its adoption 111
8.3.6 OTHER CANCERS 112
9 RADIOTHERAPY MARKET, BY END USER 114
9.1 INTRODUCTION 115
9.1.1 HOSPITALS 116
9.1.1.1 Increasing number of small-footprint advanced radiotherapy products promoting their adoption in hospitals 116
9.1.2 INDEPENDENT RADIOTHERAPY CENTERS 117
9.1.2.1 Rising consolidation of healthcare networks is challenging the growth of freestanding radiotherapy centers 117
10 RADIOTHERAPY MARKET, BY REGION 119
10.1 INTRODUCTION 120
10.2 NORTH AMERICA 120
10.2.1 US 127
10.2.1.1 Growing government initiatives boosting the adoption of radiotherapy in the US 127
10.2.2 CANADA 129
10.2.2.1 Rising cancer incidence driving the demand for radiotherapy in Canada 129
10.3 EUROPE 132
10.3.1 GERMANY 139
10.3.1.1 Increasing awareness of novel and advanced radiotherapy products a key factor contributing to market growth 139
10.3.2 FRANCE 141
10.3.2.1 Growing government initiatives boosting the adoption of radiotherapy in France 141
10.3.3 UK 143
10.3.3.1 Leading market players focusing on expanding their product offerings in the UK 143
10.3.4 REST OF EUROPE 145
10.4 ASIA PACIFIC 148
10.4.1 CHINA 156
10.4.1.1 Presence of a large number of local manufactures supporting the growth of the radiotherapy market in China 156
10.4.2 JAPAN 158
10.4.2.1 Rising prevalence of cancer is driving the adoption of radiotherapy in Japan 158
10.4.3 INDIA 160
10.4.3.1 Shortage of skilled radiotherapy professionals in India is restraining market growth 160
10.4.4 REST OF ASIA PACIFIC 162
10.5 REST OF THE WORLD 165
11 COMPETITIVE LANDSCAPE 173
11.1 INTRODUCTION 173
11.2 MARKET SHARE ANALYSIS 175
11.3 COMPETITIVE SCENARIO 176
11.3.1 PRODUCT LAUNCHES AND APPROVALS 176
11.3.2 ACQUISITIONS 176
11.3.3 EXPANSIONS 177
11.3.4 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 177
11.4 VENDOR DIVE OVERVIEW 178
11.5 VENDOR INCLUSION CRITERIA 178

11.6 VENDOR DIVE 178
11.6.1 VANGUARDS 178
11.6.2 INNOVATORS 179
11.6.3 DYNAMIC PLAYERS 179
11.6.4 EMERGING COMPANIES 179
12 COMPANY PROFILES 182
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ACCURAY INCORPORATED 182
12.2 C. R. BARD, INC. 185
12.3 ELEKTA 187
12.4 HITACHI, LTD. 192
12.5 IBA (ION BEAM APPLICATIONS SA) 194
12.6 ISORAY MEDICAL, INC. 198
12.7 MEVION MEDICAL SYSTEMS, INC. 200
12.8 OPTIVUS PROTON THERAPY, INC. 202
12.9 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 203
12.10 P-CURE LTD. 204
12.11 PROVISION HEALTHCARE, LLC. 205
12.12 SUMITOMO HEAVY INDUSTRIES, LTD 207
12.13 THERAGENICS CORPORATION 209
12.14 VARIAN MEDICAL SYSTEMS, INC. 210
12.15 VIEWRAY INC. 215

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 218
13.1 DISCUSSION GUIDE 218
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 223
13.3 AVAILABLE CUSTOMIZATIONS 225
13.4 RELATED REPORTS 225
13.5 AUTHOR DETAILS 226

LIST OF TABLES

TABLE 1 NATIONAL AVERAGE MEDICARE REIMBURSEMENT: OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) ESTIMATED PER COURSE 54
TABLE 2 RADIOTHERAPY MARKET, BY PRODUCT TYPE, 2016–2023 (USD MILLION) 59
TABLE 3 EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT TYPE,
2016–2023 (USD MILLION) 60
TABLE 4 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 61
TABLE 5 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LINEAR ACCELERATORS,
BY TYPE, 2016–2023 (USD MILLION) 61
TABLE 6 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LINEAR ACCELERATORS,
BY REGION, 2016–2023 (USD MILLION) 62
TABLE 7 CONVENTIONAL LINEAR ACCELERATORS MARKET, BY REGION,
2016–2023 (USD MILLION) 62
TABLE 8 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINAC MARKET,
BY PRODUCT TYPE, 2016–2023 (USD MILLION) 63
TABLE 9 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY REGION, 2016–2023 (USD MILLION) 64
TABLE 10 GAMMA KNIFE MARKET, BY REGION, 2016–2023 (USD MILLION) 65
TABLE 11 CYBERKNIFE MARKET, BY REGION, 2016–2023 (USD MILLION) 66
TABLE 12 TOMOTHERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 67
TABLE 13 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PARTICLE THERAPY SYSTEMS,
BY PRODUCT TYPE, 2016–2023 (USD MILLION) 67
TABLE 14 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PARTICLE THERAPY SYSTEMS,
BY REGION, 2016–2023 (USD MILLION) 68
TABLE 15 PARTICLE THERAPY SYSTEMS MARKET FOR CYCLOTRONS, BY REGION,
2016–2023 (USD MILLION) 69
TABLE 16 PARTICLE THERAPY SYSTEMS MARKET FOR SYNCHROTRONS, BY REGION,
2016–2023 (USD MILLION) 69
TABLE 17 PARTICLE THERAPY SYSTEMS MARKET FOR SYNCHROCYCLOTRONS,
BY REGION, 2016–2023 (USD MILLION) 70
TABLE 18 EXTERNAL BEAM RADIOTHERAPY MARKET FOR CONVENTIONAL COBALT-60 TELETHERAPY UNITS, BY REGION, 2016–2023 (USD MILLION) 71
TABLE 19 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2016–2023 (USD MILLION) 73
TABLE 20 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 73
TABLE 21 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR SEEDS,
BY REGION, 2016–2023 (USD MILLION) 74
TABLE 22 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR APPLICATORS, BY REGION, 2016–2023 (USD MILLION) 75
TABLE 23 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR AFTERLOADERS, BY REGION, 2016–2023 (USD MILLION) 76
TABLE 24 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR ELECTRONIC BRACHYTHERAPY PRODUCTS, BY REGION, 2016–2023 (USD MILLION) 77
TABLE 25 RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 81
TABLE 26 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 82
TABLE 27 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 83
TABLE 28 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 84
TABLE 29 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 85
TABLE 30 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 85
TABLE 31 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 86
TABLE 32 VOLUMETRIC ARC THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 87
TABLE 33 TOMOTHERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 87
TABLE 34 STEREOTACTIC THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 89
TABLE 35 PARTICLE THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 90
TABLE 36 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 92
TABLE 37 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY REGION, 2016–2023 (USD MILLION) 92
TABLE 38 LOW-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 93
TABLE 39 HIGH-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 94
TABLE 40 PULSED-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION,
2016–2023 (USD MILLION) 95
TABLE 41 RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2016-2023 (USD MILLION) 98
TABLE 42 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE,
2016-2023 (USD MILLION) 99
TABLE 43 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2016-2023 (USD MILLION) 100
TABLE 44 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2016-2023 (USD MILLION) 101
TABLE 45 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER,
BY REGION, 2016-2023 (USD MILLION) 102
TABLE 46 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD AND NECK CANCER, BY REGION, 2016-2023 (USD MILLION) 103
TABLE 47 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2016-2023 (USD MILLION) 104
TABLE 48 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR OTHER CANCERS, BY REGION, 2016-2023 (USD MILLION) 105
TABLE 49 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 107
TABLE 50 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR PROSTATE CANCER, BY REGION, 2016-2023 (USD MILLION) 108
TABLE 51 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR GYNECOLOGICAL CANCER, BY REGION, 2016-2023 (USD MILLION) 109
TABLE 52 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR BREAST CANCER, BY REGION, 2016-2023 (USD MILLION) 110
TABLE 53 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR CERVICAL CANCER, BY REGION, 2016-2023 (USD MILLION) 111
TABLE 54 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR PENILE CANCER, BY REGION, 2016-2023 (USD MILLION) 112
TABLE 55 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET
FOR OTHER CANCERS, BY REGION, 2016-2023 (USD MILLION) 113
TABLE 56 RADIOTHERAPY MARKET, BY END USER, 2016–2023 (USD MILLION) 115
TABLE 57 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2016–2023 (USD MILLION) 117
TABLE 58 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS,
BY REGION, 2016–2023 (USD MILLION) 118
TABLE 59 RADIOTHERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 120
TABLE 60 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 122
TABLE 61 NORTH AMERICA: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 122
TABLE 62 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 122
TABLE 63 NORTH AMERICA: LINEAR ACCELERATORS MARKET, BY TYPE,
2016–2023 (USD MILLION) 123
TABLE 64 NORTH AMERICA: STEREOTACTIC ADVANCED LINEAR ACCELERATORS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 65 NORTH AMERICA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE,
2016–2023 (USD MILLION) 123
TABLE 66 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 124
TABLE 67 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 124
TABLE 68 NORTH AMERICA: INTENSITY-MODULATED RADIOTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 69 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 70 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 71 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 72 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER,
2016–2023 (USD MILLION) 127
TABLE 73 US: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 74 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 128
TABLE 75 US: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 128
TABLE 76 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 129
TABLE 77 CANADA: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 78 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 130
TABLE 79 CANADA: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 131
TABLE 80 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 131
TABLE 81 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 134
TABLE 82 EUROPE: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 134
TABLE 83 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 134
TABLE 84 EUROPE: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 85 EUROPE: STEREOTACTIC ADVANCED LINEAR ACCELERATORS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 86 EUROPE: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE,
2016–2023 (USD MILLION) 136
TABLE 87 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 136
TABLE 88 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 89 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 90 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 91 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 92 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 93 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2016–2023 (USD MILLION) 139
TABLE 94 GERMANY: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 140
TABLE 95 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 140
TABLE 96 GERMANY: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 140
TABLE 97 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 141
TABLE 98 FRANCE: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 99 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 142
TABLE 100 FRANCE: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 101 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 143
TABLE 102 UK: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 144
TABLE 103 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 144
TABLE 104 UK: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 145
TABLE 105 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 145
TABLE 106 REST OF EUROPE: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 107 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 146
TABLE 108 REST OF EUROPE: LINEAR ACCELERATORS MARKET, BY TYPE,
2016–2023 (USD MILLION) 147
TABLE 109 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 147
TABLE 110 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 150
TABLE 111 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 112 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 150
TABLE 113 ASIA PACIFIC: LINEAR ACCELERATORS MARKET, BY TYPE,
2016–2023 (USD MILLION) 151
TABLE 114 ASIA PACIFIC: STEREOTACTIC ADVANCED LINEAR ACCELERATORS MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 151
TABLE 115 ASIA PACIFIC: PARTICLE THERAPY SYSTEMS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 152
TABLE 116 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 152
TABLE 117 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 153
TABLE 118 APAC: INTENSITY-MODULATED RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 153
TABLE 119 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 154
TABLE 120 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 154
TABLE 121 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 122 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2016–2023 (USD MILLION) 155
TABLE 123 CHINA: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 157
TABLE 124 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 157
TABLE 125 CHINA: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 157
TABLE 126 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 158
TABLE 127 JAPAN: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 159
TABLE 128 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 159
TABLE 129 JAPAN: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 159
TABLE 130 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 160
TABLE 131 INDIA: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 161
TABLE 132 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 161
TABLE 133 INDIA: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 162
TABLE 134 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 162
TABLE 135 ROAPAC: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 136 ROAPAC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 163
TABLE 137 ROAPAC: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 164
TABLE 138 ROAPAC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 164
TABLE 139 ROW: RADIOTHERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 167
TABLE 140 ROW: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 167
TABLE 141 ROW: LINEAR ACCELERATORS MARKET, BY TYPE, 2016–2023 (USD MILLION) 167
TABLE 142 ROW: STEREOTACTIC ADVANCED LINEAR ACCELERATORS MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 168
TABLE 143 ROW: PARTICLE THERAPY SYSTEMS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 168
TABLE 144 ROW: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 169
TABLE 145 ROW: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 146 ROW: INTENSITY-MODULATED RADIOTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 147 ROW: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 148 ROW: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 171
TABLE 149 ROW: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 171
TABLE 150 ROW: RADIOTHERAPY MARKET, BY END USER, 2016–2023 (USD MILLION) 172


LIST OF FIGURES

FIGURE 1 RADIOTHERAPY MARKET: RESEARCH METHODOLOGY STEPS 24
FIGURE 2 RESEARCH DESIGN 25
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL RADIOTHERAPY MARKET 29
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 29
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 31
FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 31
FIGURE 7 DATA TRIANGULATION METHODOLOGY 33
FIGURE 8 RADIOTHERAPY MARKET, BY TYPE, 2018 (USD MILLION) 35
FIGURE 9 EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT TYPE,
2018 VS. 2023 (USD MILLION) 36
FIGURE 10 INTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT TYPE,
2018 VS. 2023 (USD MILLION) 37
FIGURE 11 EXTERNAL BEAM RADIOTHERAPY MARKET SHARE, BY APPLICATION,
2018 VS. 2023 37
FIGURE 12 RADIOTHERAPY MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 38
FIGURE 13 RADIOTHERAPY MARKET: GEOGRAPHICAL SNAPSHOT 39
FIGURE 14 RISING CANCER PREVALENCE ACROSS THE GLOBE IS DRIVING GROWTH IN THE RADIOTHERAPY MARKET 40
FIGURE 15 IMAGE-GUIDED RADIOTHERAPY TO DOMINATE THE EXTERNAL BEAM RADIOTHERAPY MARKET IN EUROPE IN 2018 41
FIGURE 16 AFTERLOADERS TO REGISTER THE HIGHEST CAGR IN THE MARKET DURING THE FORECAST PERIOD 42
FIGURE 17 OTHERS CANCER APPLICATION SEGMENT TO GROW AT THE FASTEST RATE IN THE EXTERNAL BEAM RADIOTHERAPY MARKET DURING THE FORECAST PERIOD 43
FIGURE 18 NORTH AMERICA TO DOMINATE THE RADIOTHERAPY END USER MARKET IN 2018 44
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
(2018–2023) 45
FIGURE 20 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2012–2020 (THOUSAND) 49
FIGURE 22 PARTICLE THERAPY SYSTEMS TO REGISTER HIGHEST GROWTH IN THE EXTERNAL BEAM RADIOTHERAPY MARKET DURING THE FORECAST PERIOD 60
FIGURE 23 SEEDS TO DOMINATE INTERNAL BEAM RADIOTHERAPY MARKET DURING THE FORECAST PERIOD 72
FIGURE 24 IMAGE-GUIDED RADIOTHERAPY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE EXTERNAL BEAM RADIOTHERAPY MARKET IN 2018 82
FIGURE 25 NUMBER OF PARTICLE THERAPY FACILITIES PRESENT (AS OF OCTOBER 2018) & UNDER CONSTRUCTION ACROSS THE GLOBE 90
FIGURE 26 HIGH-DOSE-RATE BRACHYTHERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INTERNAL BEAM RADIOTHERAPY MARKET IN 2018 91
FIGURE 27 PROSTATE CANCER TO DOMINATE THE EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET DURING THE FORECAST PERIOD 99
FIGURE 28 BREAST CANCER TO REGISTER HIGHEST GROWTH IN INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET 106
FIGURE 29 HOSPITALS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 115
FIGURE 30 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 121
FIGURE 31 EUROPE: RADIOTHERAPY MARKET SNAPSHOT 133
FIGURE 32 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 149
FIGURE 33 ROW: RADIOTHERAPY MARKET SNAPSHOT 166
FIGURE 34 KEY DEVELOPMENTS IN THE RADIOTHERAPY MARKET BETWEEN 2015–2018 174
FIGURE 35 RADIOTHERAPY MARKET SHARE, BY KEY PLAYER, 2017 175
FIGURE 36 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) 180
FIGURE 37 COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS) 181
FIGURE 38 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2018) 182
FIGURE 39 C. R. BARD, INC.: COMPANY SNAPSHOT (2016) 185
FIGURE 40 ELEKTA AB: COMPANY SNAPSHOT (2017) 187
FIGURE 41 HITACHI: COMPANY SNAPSHOT (2017) 192
FIGURE 42 ION BEAM APPLICATIONS SA: COMPANY SNAPSHOT (2017) 194
FIGURE 43 ISORAY MEDICAL, INC.: COMPANY SNAPSHOT (2018) 198
FIGURE 44 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT (2016) 207
FIGURE 45 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2018) 210
FIGURE 46 VIEWRAY, INC.: COMPANY SNAPSHOT (2017) 215


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[放射線治療の世界市場予測(~2023年)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆